EyePoint — Third Quarter 2026 Earnings Summary

EyePoint, Inc. reported a net loss of $95.6 million for the third quarter ended September 30, 2026, driven by $97.6 million in operating expenses primarily related to ongoing Phase 3 clinical trials. The company announced a strategic shift to prioritize its DURAVYU program for diabetic macular edema (DME), following Phase 3 trials for wet AMD that did not meet primary non-inferiority endpoints but showed significant reductions in treatment burden. To extend its financial runway, EyePoint implemented a workforce reduction of approximately 53%, expecting to generate $30 million in annualized savings. As of September 30, 2026, the company held $118 million in cash, cash equivalents, and short-term investments, with operations funded through the late third quarter of 2027.